Phase II study of irinotecan plus capecitabine in anthracycline-and taxane-pretreated patients with metastatic breast cancer

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 152-159

  Lee, Keun Seok ^a   Park, In Hae ^a   Nam, Byung Ho ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

Author keywords

Capecitabine; Chemotherapy; Irinotecan; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; BICARBONATE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MAGNESIUM OXIDE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; TRASTUZUMAB; URSODEOXYCHOLIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST METASTASIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 84873088845     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9824-8     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249. doi: 10.3322/caac.20006
2. Won Y-J, Sung J, Jung K-W, Kong H-J, Park S, Shin H-R, Park E-C, Ahn Y-O, Hwang IK, Lee D-H (2009) Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 41(3):122-131. doi: 10.4143/crt.2009.41.3.122
3. Gralow JR (2005) Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 89(Suppl 1):S9-S15. doi: 10.1007/s10549-005-0143-z
4. Rivera E (2010) Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol 33(2):176-185. doi: 10.1097/COC.0b013e3181931049
5. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274-1281
6. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291-297. doi: 10.1007/s002800050043
7. Venturini M, Paridaens R, Rossner D, Vaslamatzis MM, Nortier JW, Salzberg M, Rodrigues H, Bell R (2007) An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology 72(1-2):51-57. doi: 10.1159/000111094
8. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43(2):186-189. doi: 10.1080/02841860310023165
9. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S (2003) Multicenter phase II study of oral capecitabine (Xeloda(″)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14(8):1227-1233. doi: 10.1093/annonc/mdg346
10. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40(4):536-542. doi: 10.1016/j.ejca.2003.11.007
11. Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8(9):837-855
12. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14):2849-2855. doi: 10.1200/JCO.2004.10.047
13. Shigeoka Y, Itoh K, Igarashi T, Ishizawa K, Saeki T, Fujii H, Minami H, Imoto S, Sasaki Y (2001) Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol 31(8):370-374. doi: 10.1093/jjco/hye082
14. O'Connor T, Rustum Y, Levine E, Creaven P (2008) A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol 61(1):125-131. doi: 10.1007/s00280-007-0456-1
15. Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL (2005) S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol 56(5):447-454. doi: 10.1007/s00280-004-0951-6
16. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R (2004) Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91(7):1245-1250. doi: 10.1038/sj.bjc.6602139
17. Han JY, Lee DH, Lee SY, Park CG, Kim HY, Lee HG, Lee JJ, Kim HT, Lee JS (2005) Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer 104(12):2759-2765. doi: 10.1002/cncr.21563
18. CTEP: Common Terminology Criteria for Adverse Events v3.0 (CTCAE), Cancer Therapy Evaluation Program. Bethestha, MD, National Cancer Institute. 2003. doi: 10.1016/S1053-4296(03)00031-6
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216. doi: 10.1093/jnci/92.3.205
20. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
22. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210-5217. doi: 10.1200/JCO.2007.12.6557
23. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22(8):1382-1388
24. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24(15):2237-2244. doi: 10.1200/JCO.2004.07.173
25. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27(15):2457-2465. doi: 10.1200/JCO.2008.19.0314
26. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T (1998) Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1406(3):267-273. doi: 10.1016/S0925-4439(98)00013- 1
27. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K (2001) Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92(2):269-275. doi: 10.1002/1097-0215(200102
28. Takeda Y, Tsuduki E, Izumi S, Hojo M, Kamimura M, Naka G, Kobayashi K, Kudo K (2005) A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. Br J Cancer 93(12):1341-1349. doi: 10.1038/sj.bjc.6602866